VANDA PHARMACEUTICALS INC (VNDA)

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 203 full-time employees. The company went IPO on 2006-04-12. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The firm also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Company Info

VANDA PHARMACEUTICALS INC

Suite 300E, 2200 Pennsylvania Ave Nw

WASHINGTON WASHINGTON DC 20037

P: 12027343400

CEO: Mihael H. Polymeropoulos

Employees: 203

Website: https://www.vandapharma.com/